IP Verse

Wyeth competitive analysis

Latest publications and patents of Wyeth New

Explore the latest publications and patents granted to Wyeth, showcasing their recent innovations and technological advancements.

Last updated on: Sep 30, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Wyeth

EP2676679
Aug 28, 2024Formulations Which Stabilize And Inhibit Precipitation Of Immunogenic CompositionsPatent Maintained As Amended
EP3246044
Apr 10, 2024Stable Formulations Of Neisseria Meningitidis Rlp2086 AntigensPatent Maintained As Amended
EP3572073
Dec 20, 2023Lyophilization Above CollapseGranted And Under Opposition
EP3175853
Nov 1, 2023Antineoplastic Combinations Of Neratinib And CapecitabineGranted And Under Opposition
EP1942868
Oct 4, 2023Sodium Chloride Solution For Drug Reconstitution Or DilutionPatent Maintained As Amended
EP3263571
Aug 23, 2023Crystal Form Of (R)-N-Methylnaltrexone Bromide And Uses ThereofPatent Maintained As Amended
EP3000467
Mar 1, 2023Treatment Regimen Utilizing Neratinib For Breast CancerGranted And Under Opposition
EP2498756
Feb 15, 2023Tablet Formulations Of Neratinib MaleatePatent Maintained As Amended
EP3255141
Dec 1, 2021Production Of Antibodies With Improved Glycosylation PatternRevoked
EP2357250
Oct 6, 2021Production Of PolypeptidesRevoked

Latest patents of Wyeth opposed by its competitors

Explore Wyeth's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2676679
Aug 28, 2024Formulations Which Stabilize And Inhibit Precipitation Of Immunogenic Compositions3
EP3246044
Apr 10, 2024Stable Formulations Of Neisseria Meningitidis Rlp2086 Antigens1
EP3572073
Dec 20, 2023Lyophilization Above Collapse1
EP3175853
Nov 1, 2023Antineoplastic Combinations Of Neratinib And Capecitabine1
EP1942868
Oct 4, 2023Sodium Chloride Solution For Drug Reconstitution Or Dilution1
EP3263571
Aug 23, 2023Crystal Form Of (R)-N-Methylnaltrexone Bromide And Uses Thereof1
EP3000467
Mar 1, 2023Treatment Regimen Utilizing Neratinib For Breast Cancer3
EP2498756
Feb 15, 2023Tablet Formulations Of Neratinib Maleate1
EP3255141
Dec 1, 2021Production Of Antibodies With Improved Glycosylation Pattern2
EP2357250
Oct 6, 2021Production Of Polypeptides2

Latest PTAB cases involving Wyeth

Discover the latest PTAB cases involving Wyeth, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 6, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Wyeth

IPR2017-01223Mar 31, 2017MERCK SHARP & DOHMEWYETHInstitution Denied
IPR2017-01215Mar 30, 2017MERCK SHARP & DOHMEWYETHInstitution Denied
IPR2017-01211Mar 30, 2017MERCK SHARP & DOHMEWYETHInstitution Denied
IPR2017-01194Mar 29, 2017MERCK SHARP & DOHMEWYETHInstitution Denied
PGR2017-00017Mar 24, 2017MERCK SHARP & DOHMEWYETHInstitution Denied
PGR2017-00016Mar 22, 2017MERCK SHARP & DOHMEWYETHInstitution Denied
IPR2017-00390Dec 2, 2016MERCK SHARP & DOHMEWYETHFinal Written Decision
IPR2017-00380Dec 1, 2016MERCK SHARP & DOHMEWYETHFinal Written Decision
IPR2017-00378Dec 1, 2016MERCK SHARP & DOHMEWYETHFinal Written Decision
IPR2015-00873Mar 12, 2015APOTEXWYETHInstitution Denied

Peer Comparison New

IP litigation analysis comparing Wyeth with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
WYETH - 32 - 12Non-Active
HOFFMANN EITLE147 - - - Highly Aggressive
MERCK SHARP & DOHME2042545Highly Aggressive
STRAWMAN331 - - - Highly Aggressive